29 years of historical data (1996–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Protalix BioTherapeutics, Inc. trades at 78.7x earnings, 128% above its 5-year average of 34.6x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a premium of 232%. On a free-cash-flow basis, the stock trades at 29.6x P/FCF, 43% above the 5-year average of 20.6x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $218M | $152M | $147M | $66M | $37M | $106M | $49M | $46M | $87M | $451M | $968M |
| Enterprise Value | $204M | $138M | $151M | $83M | $31M | $152M | $92M | $56M | $88M | $465M | $964M |
| P/E Ratio → | 78.69 | 51.37 | 17.80 | — | — | — | — | — | — | — | 16.72 |
| P/S Ratio | 4.09 | 2.85 | 2.24 | 1.39 | 0.96 | 1.68 | 0.89 | 1.34 | 4.11 | 49.05 | 221.86 |
| P/B Ratio | 5.40 | 3.53 | 4.37 | — | — | — | — | — | — | — | 89.05 |
| P/FCF | 29.55 | 20.62 | — | — | — | — | — | — | — | — | — |
| P/OCF | 25.18 | 17.57 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Protalix BioTherapeutics, Inc.'s enterprise value stands at 39.1x EBITDA, 52% above its 5-year average of 25.8x. The Healthcare sector median is 13.8x, placing the stock at a 183% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.59 | 2.30 | 1.74 | 0.81 | 2.42 | 1.68 | 1.63 | 4.16 | 50.59 | 220.88 |
| EV / EBITDA | 39.11 | 26.46 | 12.94 | — | — | 37.87 | — | — | — | — | — |
| EV / EBIT | 52.14 | 26.49 | 12.84 | — | — | 48.27 | — | — | — | — | — |
| EV / FCF | — | 18.69 | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Protalix BioTherapeutics, Inc. earns an operating margin of 7.3%. Operating margins have expanded from -27.3% to 7.3% over the past 3 years, signaling improving operational efficiency. ROE of 7.6% is modest. ROIC of 8.8% represents adequate returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 54.5% | 54.5% | 64.9% | 58.9% | 57.4% | 82.7% | 80.1% | 72.8% | 27.7% | 8.7% | 83.3% |
| Operating Margin | 7.3% | 7.3% | 16.0% | -27.3% | -53.4% | 4.3% | -19.6% | -56.4% | -163.8% | -360.5% | -542.4% |
| Net Profit Margin | 5.5% | 5.5% | 12.7% | -31.3% | -71.9% | -10.4% | -33.4% | -77.3% | -395.9% | -319.2% | 1329.9% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 7.6% | 7.6% | 72.5% | — | — | — | — | — | — | -6411.6% | 533.8% |
| ROA | 3.7% | 3.7% | 11.9% | -23.1% | -39.0% | -11.5% | -34.3% | -39.7% | -108.0% | -32.7% | 66.1% |
| ROIC | 8.8% | 8.8% | 36.2% | -170.5% | -406.7% | — | — | — | — | -457.5% | — |
| ROCE | 9.0% | 9.0% | 33.6% | -40.8% | -186.5% | — | -52.3% | -45.3% | -105.4% | -65.0% | -34.2% |
Solvency and debt-coverage ratios — lower is generally safer
Protalix BioTherapeutics, Inc. carries a Debt/EBITDA ratio of 1.1x, which is manageable (66% below the sector average of 3.1x). The company holds a net cash position — cash of $20M exceeds total debt of $6M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 3.7x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.13 | 0.82 | — | — | — | — | — | — | — | 6.63 |
| Debt / EBITDA | 1.06 | 1.06 | 2.38 | — | — | 16.05 | — | — | — | — | — |
| Net Debt / Equity | — | -0.33 | 0.12 | — | — | — | — | — | — | — | -0.39 |
| Net Debt / EBITDA | -2.73 | -2.73 | 0.35 | — | — | 11.50 | — | — | — | — | — |
| Debt / FCF | — | -1.93 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 3.69 | 3.69 | 3.29 | -5.15 | -2.72 | 0.28 | -1.35 | -2.51 | -3.55 | -7.91 | -6.34 |
Net cash position: cash ($20M) exceeds total debt ($6M)
Short-term solvency ratios and asset-utilisation metrics
Protalix BioTherapeutics, Inc.'s current ratio of 2.34x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 1.52x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 1.38x to 2.34x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.34 | 2.34 | 1.54 | 1.38 | 1.86 | 0.64 | 0.81 | 2.09 | 2.75 | 1.09 | 7.64 |
| Quick Ratio | 1.52 | 1.52 | 1.12 | 0.87 | 1.32 | 0.49 | 0.61 | 1.75 | 2.41 | 1.01 | 7.13 |
| Cash Ratio | 1.36 | 1.36 | 0.98 | 0.68 | 1.18 | 0.45 | 0.44 | 1.49 | 2.25 | 0.96 | 6.80 |
| Asset Turnover | — | 0.73 | 0.78 | 0.85 | 0.52 | 0.93 | 1.20 | 0.56 | 0.29 | 0.11 | 0.04 |
| Inventory Turnover | 1.14 | 1.14 | 1.21 | 1.17 | 0.91 | 0.83 | 1.34 | 1.09 | 1.94 | 1.60 | 0.13 |
| Days Sales Outstanding | — | 19.88 | 29.38 | 35.14 | 32.76 | 11.61 | 31.37 | 50.41 | 29.80 | 27.50 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Protalix BioTherapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 1.3% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.3% | 1.9% | 5.6% | — | — | — | — | — | — | — | 6.0% |
| FCF Yield | 3.4% | 4.9% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $81M | $82M | $48M | $44M | $29M | $15M | $15M | $13M | $101M | $95M |
Compare PLX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| PLXYou | $218M | 78.7 | 39.1 | 29.6 | 54.5% | 7.3% | 7.6% | 8.8% | 1.1 |
| AGIO | $2.3T | -4.2 | — | — | 88.3% | -873.9% | -30.2% | -26.6% | — |
| VRTX | $126B | 32.4 | 26.6 | 39.5 | 86.2% | 39.1% | 22.5% | 22.8% | 0.8 |
| ASND | $14B | -54.7 | — | 278.6 | 85.1% | -18.9% | — | -69.1% | — |
| BBIO | $13B | -17.5 | — | — | 94.4% | -113.3% | — | — | — |
| BMRN | $12B | 34.3 | 18.2 | 16.4 | 77.1% | 16.6% | 5.7% | 7.4% | 1.0 |
| COGT | $6B | -15.2 | — | — | — | — | -73.7% | -66.4% | — |
| PTCT | $5B | 8.8 | 5.6 | — | — | 50.1% | — | — | 0.5 |
| MIRM | $5B | -196.4 | — | 87.3 | 80.8% | -4.2% | -8.6% | -5.1% | — |
| FOLD | $4B | -79.8 | 139.5 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
| CRNX | $4B | -8.3 | — | — | 80.1% | -9534.5% | -40.2% | -37.8% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 29 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how PLX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonProtalix BioTherapeutics, Inc.'s current P/E ratio is 78.7x. The historical average is 28.6x. This places it at the 100th percentile of its historical range.
Protalix BioTherapeutics, Inc.'s current EV/EBITDA is 39.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 25.8x.
Protalix BioTherapeutics, Inc.'s return on equity (ROE) is 7.6%. The historical average is -58.4%.
Based on historical data, Protalix BioTherapeutics, Inc. is trading at a P/E of 78.7x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Protalix BioTherapeutics, Inc. has 54.5% gross margin and 7.3% operating margin.
Protalix BioTherapeutics, Inc.'s Debt/EBITDA ratio is 1.1x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.